Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals leads CF therapy market with TRIKAFTA, KAFTRIO and SYMDEKO, expanding into sickle cell, kidney disease and gene‑editing collaborations.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 6,100
HQ: Boston

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
VRTX	Vertex Pharmaceuticals Inc. Cap: 120.1B \| P/E: 33.0	EQUITY	NMS	USD	US92532F1003	Active	📈